These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 30031022)

  • 1. PK/PD-based adaptive tailoring of oseltamivir doses to treat within-host influenza viral infections.
    Montaseri G; Boianelli A; Hernandez-Vargas EA; Meyer-Hermann M
    Prog Biophys Mol Biol; 2018 Nov; 139():31-42. PubMed ID: 30031022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection.
    Boianelli A; Sharma-Chawla N; Bruder D; Hernandez-Vargas EA
    Front Cell Infect Microbiol; 2016; 6():60. PubMed ID: 27379214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study Design.
    Reddy MB; Yang KH; Rao G; Rayner CR; Nie J; Pamulapati C; Marathe BM; Forrest A; Govorkova EA
    PLoS One; 2015; 10(10):e0138069. PubMed ID: 26460484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic determinants of oseltamivir efficacy using data from phase 2 inoculation studies.
    Rayner CR; Bulik CC; Kamal MA; Reynolds DK; Toovey S; Hammel JP; Smith PF; Bhavnani SM; Van Wart SA; Ambrose PG; Forrest A
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3478-87. PubMed ID: 23669386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oseltamivir for influenza infection in children: risks and benefits.
    Esposito S; Principi N
    Expert Rev Respir Med; 2016; 10(1):79-87. PubMed ID: 26616633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of oseltamivir in neonates, infants and children.
    Standing JF; Tsolia M; Lutsar I
    Infect Disord Drug Targets; 2013 Feb; 13(1):6-14. PubMed ID: 23675922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The in vivo efficacy of neuraminidase inhibitors cannot be determined from the decay rates of influenza viral titers observed in treated patients.
    Palmer J; Dobrovolny HM; Beauchemin CA
    Sci Rep; 2017 Jan; 7():40210. PubMed ID: 28067324
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuraminidase inhibitor resistance in influenza viruses.
    Reece PA
    J Med Virol; 2007 Oct; 79(10):1577-86. PubMed ID: 17705169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.
    Lam H; Jeffery J; Sitar DS; Aoki FY
    Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Balance between Inhibitor Binding and Substrate Processing Confers Influenza Drug Resistance.
    Jiang L; Liu P; Bank C; Renzette N; Prachanronarong K; Yilmaz LS; Caffrey DR; Zeldovich KB; Schiffer CA; Kowalik TF; Jensen JD; Finberg RW; Wang JP; Bolon DNA
    J Mol Biol; 2016 Feb; 428(3):538-553. PubMed ID: 26656922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective surveillance of antiviral resistance in hospitalized infants less than 12 months of age with A(H3N2) influenza infection and treated with oseltamivir.
    Rath B; Chen X; Spies V; Muehlhans S; Obermeier P; Tief F; Seeber L; Karsch K; Milde J; Skopnik H; Schweiger B; Duwe SC
    Antivir Ther; 2017; 22(6):515-522. PubMed ID: 28205506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics.
    Kamal MA; Smith PF; Chaiyakunapruk N; Wu DBC; Pratoomsoot C; Lee KKC; Chong HY; Nelson RE; Nieforth K; Dall G; Toovey S; Kong DCM; Kamauu A; Kirkpatrick CM; Rayner CR
    Br J Clin Pharmacol; 2017 Jul; 83(7):1580-1594. PubMed ID: 28176362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1.
    Renaud C; Kuypers J; Englund JA
    J Clin Virol; 2011 Oct; 52(2):70-8. PubMed ID: 21684202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Oral and Intravenous Oseltamivir Treatment of Severe Influenza B Virus Infection Requiring Organ Replacement Therapy.
    Karsch K; Chen X; Miera O; Peters B; Obermeier P; Francis RC; Amann V; Duwe S; Fraaij P; Heider A; de Zwart M; Berger F; Osterhaus A; Schweiger B; Rath B
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):155-164. PubMed ID: 26994602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial.
    Fry AM; Goswami D; Nahar K; Sharmin AT; Rahman M; Gubareva L; Azim T; Bresee J; Luby SP; Brooks WA
    Lancet Infect Dis; 2014 Feb; 14(2):109-18. PubMed ID: 24268590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of different oseltamivir regimens on treating influenza A virus infection and resistance emergence: insights from a modelling study.
    Canini L; Conway JM; Perelson AS; Carrat F
    PLoS Comput Biol; 2014 Apr; 10(4):e1003568. PubMed ID: 24743564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oseltamivir boosts 2009 H1N1 virus infectivity in vitro.
    Lin X; Zhou J; Zhang Y; Wu J; Zhang F; Li Z; Zhang Y; Bi S; Shu Y; Wang Y
    Biochem Biophys Res Commun; 2009 Dec; 390(4):1305-8. PubMed ID: 19879239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.
    Abed Y; Baz M; Boivin G
    J Infect Dis; 2009 Jan; 199(2):180-3. PubMed ID: 19046066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unexpected platelets elevation in a patient with idiopathic thrombocytopenia treated with oseltamivir for influenza infection.
    Bigot P; Auffret M; Gautier S; Weinborn M; Ettahar NK; Coupé P
    Fundam Clin Pharmacol; 2016 Oct; 30(5):483-5. PubMed ID: 27343486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.